Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
Neville-Webbe
Helen L
HL
Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, United Kingdom. h.l.nevillewebbe@sheffield.ac.uk
Rostami-Hodjegan
Amin
A
Evans
Catherine A
CA
Coleman
Robert E
RE
Holen
Ingunn
I
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000473:pathology / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D004224:Diterpenes / Q000494:pharmacology; D004317:Doxorubicin / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008798:Mevalonic Acid / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors; D014407:Tumor Cells, Cultured; D000077211:Zoledronic Acid
D000903:Antibiotics, Antineoplastic; D004164:Diphosphonates; D004224:Diterpenes; D007093:Imidazoles; D000077211:Zoledronic Acid; D004317:Doxorubicin; C017338:geranylgeraniol; D008798:Mevalonic Acid